Immediate Impact

34 standout
Sub-graph 1 of 17

Citing Papers

Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
2024 Standout
Renal cell carcinoma
2024 Standout
2 intermediate papers

Works of C J Davis being referenced

Renal oncocytoma and carcinoma: failure of differentiation with CT.
1993
Air-flow limitation in myasthenia gravis. The effect of acetylcholinesterase inhibitor therapy on air-flow limitation.
1983

Author Peers

Author Last Decade Papers Cites
C J Davis 476 357 194 13 614
William R. Morgan 452 173 57 14 617
Raul Mancilla-Jimenez 413 312 44 10 668
Han Jong Ahn 308 229 33 9 582
Wayne H. Borges 153 149 40 14 655
Anne M. Scruggs 326 261 60 14 613
Edward M. Leter 429 199 103 23 638
J. Wieslander 452 121 124 21 732
Charles P. McKay 270 158 30 16 605
J Maréchal 447 270 50 15 679
Samuel M. Aguayo 410 71 111 18 582

All Works

Loading papers...

Rankless by CCL
2026